ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA

 
• By Derrick Gingery
  
Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Industry worries that lack of mid-review communication about minor deficiencies in ANDA amendments could lengthen approval times.

More from Generics

More from Products